Top 10 Healthcare Stocks to Buy

Published on October 13, 2022 at 9:08 am by Usman Kabir in Hedge Funds, News

In this article, we discuss top 10 healthcare stocks to buy. If you want to read about some more healthcare stocks, go directly to Top 5 Healthcare Stocks to Buy.

Focus in the healthcare sector has steadily been shifting away from the coronavirus pandemic to diversification, vertical integration, and new business building in the past few months. According to a report by consulting firm McKinsey, innovation and growth have continued unabated in the healthcare industry despite persistent inflation in consumer prices. Volatile investment conditions and a tight labor market, however, continue to present operating and financial challenges for healthcare leaders.

Stephanie Allen, a leader in the global public health and social services world, told research firm Deloitte recently that COVID-19 has accelerated numerous trends in the healthcare sector, particularly around health equity and sustainability. Allen claims that shifting consumer preferences and behavior, the integration of life sciences and healthcare sector, rapidly evolving digital health technologies, new talent and care delivery models, and clinical innovation continue to be top of mind for healthcare executives globally.

Some of the top healthcare stocks to buy in this context include Thermo Fisher Scientific Inc. (NYSE:TMO), UnitedHealth Group Incorporated (NYSE:UNH), and Johnson & Johnson (NYSE:JNJ). McKinsey estimates that the healthcare sector will grow at a compound annual growth rate of 6% between 2021 and 2025, adding about $31 billion in profits during the time. The firm has also warned that profits could decline by more than $70 billion during this period if inflation continues unchecked.

Our Methodology

The companies that operate in the healthcare sector were selected for the list. In order to provide readers with some context for their investment choices, the business fundamentals and analyst ratings for the stocks are also discussed. Data from around 900 elite hedge funds tracked by Insider Monkey in the second quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.

wavebreakmedia/Shutterstock.com

Top Healthcare Stocks to Buy

10. Teladoc Health, Inc. (NYSE:TDOC)

Number of Hedge Fund Holders: 32

Teladoc Health, Inc. (NYSE:TDOC) provides virtual healthcare services in the United States and internationally. It is one of the best healthcare stocks to invest in. On August 26, the company announced that it had partnered with Cloud DX, which provides remote patient monitoring, to better serve the remote monitoring needs of patients in Canada. Under this partnership, existing remote patient monitoring services of Cloud DX platform in Canada will be enhanced with the virtual care capabilities of Teladoc.

On September 27, Deutsche Bank analyst George Hill maintained a Hold rating on Teladoc Health, Inc. (NYSE:TDOC) stock and lowered the price target to $31 from $34, noting the business of the firm had matured rapidly during the pandemic.

At the end of the second quarter of 2022, 32 hedge funds in the database of Insider Monkey held stakes worth $1.2 billion in Teladoc Health, Inc. (NYSE:TDOC), compared to 36 the preceding quarter worth $1.97 billion.

Just like Thermo Fisher Scientific Inc. (NYSE:TMO), UnitedHealth Group Incorporated (NYSE:UNH), and Johnson & Johnson (NYSE:JNJ), Teladoc Health, Inc. (NYSE:TDOC) is one of the best healthcare stocks to buy according to hedge funds.

In its Q1 2022 investor letter, RiverPark Funds, an asset management firm, highlighted a few stocks and Teladoc Health, Inc. (NYSE:TDOC) was one of them. Here is what the fund said:

“Teladoc Health, Inc. (NYSE:TDOC) is the largest telehealth provider in the US and has recently begun to expand internationally. TDOC’s platform enables an ever-expanding list of patient-doctor interactions (including those for primary health care, mental health issues and chronic condition management) to transition from an on-site visit to one that can be done remotely with full video- based interaction. TDOC provides its platform of services on both a business-to-business and direct-to-consumer basis, through monthly subscription-based relationships. For its core business-to-business clients, the company contracts with a wide range of entities, including large scale employers (the company currently contracts with over 50% of the Fortune 500), health plans, health systems, and medical insurance companies, which currently cover more than 50 million members. For these customers, the company provides a win-win-win, as patients spend no time traveling and less time waiting, doctors are more efficient seeing more patients in less time, and payers (employers and plan sponsors) save money while being able to offer a highly popular additional benefit for their employees. This B to B market is projected to be a +$100 billion market opportunity and TDOC is the clear global market leader. For its direct-to- consumer clients, the company provides a growing suite of services for individuals to have affordable access to on-demand and scheduled medical services, for which their current insurance does not provide reimbursement (such as extended mental health counseling) (…read more)

9. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Number of Hedge Fund Holders: 43

Bio-Rad Laboratories, Inc. (NYSE:BIO) manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It is one of the top healthcare stocks to invest in. On October 10, The Wall Street Journal reported that the diagnostics company was in talks with competitor Qiagen N.V for a merger deal. This deal could be worth more than $41 billion, per the report.

On August 24, Credit Suisse analyst Dan Leonard initiated coverage of Bio-Rad Laboratories, Inc. (NYSE:BIO) stock with an Outperform rating and a $715 price target, noting that the company has margin expansion opportunities in the coming months.

At the end of the second quarter of 2022, 43 hedge funds in the database of Insider Monkey held stakes worth $1.3 billion in Bio-Rad Laboratories, Inc. (NYSE:BIO), compared to 45 in the previous quarter worth $1.6 billion.

8. Zoetis Inc. (NYSE:ZTS)

Number of Hedge Fund Holders: 62

Zoetis, Inc. (NYSE:ZTS) discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It is one of the premier healthcare stocks to invest in. On September 5, the company revealed that it had acquired NewMetrica, a Scottish animal health-related digital tool developer. The drugmaker said that this acquisition will enhance their capabilities across the continuum of care and will advance their expertise in qualities of life assessments.

Among the hedge funds being tracked by Insider Monkey, California-based investment firm Arrowstreet Capital is a leading shareholder in Zoetis, Inc. (NYSE:ZTS), with 2.1 million shares worth more than $359 million.

In its Q1 2022 investor letter, Baron Funds, an asset management firm, highlighted a few stocks and Zoetis, Inc. (NYSE:ZTS) was one of them. Here is what the fund said:

“Shares of Zoetis, Inc. (NYSE:ZTS), the global leader in the discovery, development, and manufacturing of companion and farm animal health medicine and vaccines, fell along with shares of other high-multiple 2021 standout performers. We retain conviction as Zoetis recently reported a top and bottom line beat with more than 21% growth driven by dermatology, parasiticides, and recently launched monoclonal osteoarthritic treatments. The company’s 2022 guidance was in line with Street expectations, calling for 9% to 11% operational revenue growth and modest margin expansion despite heavy investment in core growth drivers.”

7. HCA Healthcare, Inc. (NYSE:HCA)

Number of Hedge Fund Holders: 63

HCA Healthcare, Inc. (NYSE:HCA) provides healthcare services in the United States. It is one of the major healthcare stocks to invest in. On June 23, the company announced that it was partnering with Mckesson, a drug distributor, for a joint venture to create a fully integrated oncology research organization combining their respective research arms. This joint venture focuses on expanding clinical research services to improve the risk of cancer and treatment options for patients.

On September 16, investment advisory Raymond James maintained an Outperform rating on HCA Healthcare, Inc. (NYSE:HCA) stock and raised the price target to $250 from $230. Analyst John Ransom issued the ratings update.

At the end of the second quarter of 2022, 63 hedge funds in the database of Insider Monkey held stakes worth $2.1 billion in HCA Healthcare, Inc. (NYSE:HCA), compared to 62 the preceding quarter worth $2.9 billion.

In its Q2 2022 investor letter, Diamond Hill Capital Management, an asset management firm, highlighted a few stocks and HCA Healthcare, Inc. (NYSE:HCA) was one of them. Here is what the fund said:

“HCA Healthcare, Inc. (NYSE:HCA) is a best-in-class operator of acute care hospitals and other health care facilities, including outpatient surgery centers. It has a strong market presence in highly attractive geographies with growing populations and low unemployment, such as Texas and Florida, which leads to a favorable payor mix. We are further attracted to its strong management team that has a stellar track record of deploying capital, and the founding family continues to own almost a quarter of the business. We initiated a position after HCA reported Q1 earnings — it reduced full year guidance due to increased labor costs and lower-than-expected acuity among COVID admissions, dampening near-term investor sentiment.”

6. CVS Health Corporation (NYSE:CVS)

Number of Hedge Fund Holders: 65

CVS Health Corporation (NYSE:CVS) provides health services in the United States. It is one of the elite healthcare stocks to invest in. On September 29, the company announced that it had extended an existing partnership with McKesson, a health information technology and pharmaceutical distribution company, to distribute pharmaceuticals of the latter through June 2027. The distribution extends to mail order and retail distribution pharmacies.

On September 7, investment advisory Evercore ISI maintained an Outperform rating on CVS Health Corporation (NYSE:CVS) stock and raised the price target to $125 from $120. Analyst Elizabeth Anderson issued the ratings update.

Among the hedge funds being tracked by Insider Monkey, Connecticut-based investment firm AQR Capital Management is a leading shareholder in CVS Health Corporation (NYSE:CVS), with 3.4 million shares worth more than $312.7 million.

In addition to Thermo Fisher Scientific Inc. (NYSE:TMO), UnitedHealth Group Incorporated (NYSE:UNH), and Johnson & Johnson (NYSE:JNJ), CVS Health Corporation (NYSE:CVS) is one of the best healthcare stocks to buy according to hedge funds.

In its Q4 2021 investor letter, ClearBridge Investments, an asset management firm, highlighted a few stocks and CVS Health Corporation (NYSE:CVS) was one of them. Here is what the fund said:

“Improving health remains a key impact theme for the portfolio, and over the past year or so we have increased our exposure to the health care sector, through the addition of CVS Health Corporation (NYSE:CVS)CVS Health Corporation (NYSE:CVS), which is well-positioned to help define the future of health care in terms of costs, quality and convenience.”

Click to continue reading and see Top 5 Healthcare Stocks to Buy.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on November 14, 2025 at by Inan Dogan, PhD

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up